Sandoz Gmbh

Other

Novartis Pharma Gmbh

Vascular Laboratory, Inc.

Fytagoras B.v.

Dieter Welzel

Hans Buhlmann

Helmut Wolf

The present invention concerns medium molecular weight heparin (MMWH 10.5 kD) for prevention and treatment of venous thromboembolism in malignant disease.

Medium molecular weight heparin

A process for prophylaxis and therapy of thrombotic processes includes preparing heparin having an average molecular weight ranging from 10 to 11.5 kd; formulating a pharmaceutical preparation which includes the heparin; and employing the pharmaceutical preparation for prophylaxis and therapy of thrombotic processes. Preferably the heparin has an average molecular weight of 10.5 kd.

Process for prophylaxis and therapy of thrombotic processes employing heparin having particular average molecular weights

5HT -receptor-antagonists for the treatment of CFS (Chronic Fatigue Syndrome) are disclosed.

Use of 5HT3-receptor antagonists for the treatment of chronic fatigue syndrome

The thrombolytic effect of the plasminogen activator pro-urokinase is improved synergistically by the co-administration of urokinase. The two components may be administered sequentially or simultaneously, and if simultaneously, either separately or as a mixture. Preferably an initial bolus injection of urokinase is followed by an infusion of pro-urokinase.

Lysis of fibrin blood clots with urokinase and pro-urokinase

Pharmaceutical preparations comprising (a) co-dergocrine or a pharmaceutically acceptable acid addition salt thereof and (b) a calcium antagonist or a pharmaceutically acceptable salt thereof, as well as the treatment of hypertension/migraine by co-administration of components (a) and (b), e.g. in the form of a composition as defined.

Pharmaceutical preparation comprising co-dergocrine and a calcium

The invention provides novel pharmaceutical compositions useful in the treatment of thrombosis in mammals, comprising a mixture of dihydroergotamine or a related ergot alkaloid and heparin.

Growing community of inventors

Nuremberg, Germany

Dieter Welzel